MiniMed Group (MMED) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of MiniMed Group (NASDAQ: MMED) recently:

• 6/4/2026 – MiniMed Group had its “buy” rating reaffirmed by Benchmark Co..
• 6/4/2026 – MiniMed Group had its “neutral” rating reaffirmed by Piper Sandler. They now have a $16.00 price target on the stock.
• 6/4/2026 – MiniMed Group had its price target lowered by Wells Fargo & Company from $26.00 to $22.00. They now have an “overweight” rating on the stock.
• 5/27/2026 – MiniMed Group is now covered by Weiss Ratings. They set a “sell (d)” rating on the stock.
• 5/18/2026 – MiniMed Group had its price target lowered by Bank of America Corporation from $27.00 to $20.00. They now have a “buy” rating on the stock.
• 5/12/2026 – MiniMed Group is now covered by Benchmark Co.. They set a “buy” rating and a $20.00 price target on the stock.
• 5/11/2026 – MiniMed Group was upgraded by Benchmark Co. to “strong-buy”.
• 4/9/2026 – MiniMed Group was upgraded by Zacks Research to “hold”.

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.